CTI BioPharma to Present at the 21st Annual Needham Virtual Healthcare Conference
CTI BioPharma Corp. (NASDAQ: CTIC) announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 1:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CTI BioPharma Corp. (NASDAQ: CTIC) announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 1:30 p.m. ET. The presentation will be available via a live webcast on their website.
CTI BioPharma is focused on developing therapies for blood-related cancers, with its FDA-approved product VONJOTM designed for myelofibrosis patients. The company is also conducting the Phase 3 PACIFICA study to further assess VONJO's efficacy.
Details
News Market Reaction – CTIC
The recorded move for CTIC in the trading session of this news was +1.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, April 6, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference at 1:30 p.m. ET. The conference will be held in a virtual meeting format.
Presentation details:
Event: 21st Annual Needham Virtual Healthcare Conference
Date: Wednesday, April 13, 2022
Time: 1:30 p.m. ET
The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.
About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJOTM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO™ is a trademark of CTI BioPharma Corp.
CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-301518407.html
SOURCE CTI BioPharma Corp.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.